Serotonergic hyperactivity as a potential factor in developmental, acquired and drug-induced synesthesia
This literature review (2013) evaluates synaesthesia and proposes that the role of excessive serotonin (genetic or drug induced) plays a role through increasing excitability and connectedness of brain regions.
Authors
- Brogaard, B.
Published
Abstract
Though synesthesia research has seen a huge growth in recent decades, and tremendous progress has been made in terms of understanding the mechanism and cause of synesthesia, we are still left mostly in the dark when it comes to the mechanistic commonalities (if any) among developmental, acquired and drug-induced synesthesia. We know that many forms of synesthesia involve aberrant structural or functional brain connectivity. Proposed mechanisms include direct projection and disinhibited feedback mechanisms, in which information from two otherwise structurally or functionally separate brain regions mix. We also know that synesthesia sometimes runs in families. However, it is unclear what causes its onset. Studies of psychedelic drugs, such as psilocybin, LSD and mescaline, reveal that exposure to these drugs can induce synesthesia. One neurotransmitter suspected to be central to the perceptual changes is serotonin. Excessive serotonin in the brain may cause many of the characteristics of psychedelic intoxication. Excessive serotonin levels may also play a role in synesthesia acquired after brain injury. In brain injury sudden cell death floods local brain regions with serotonin and glutamate. This neurotransmitter flooding could perhaps result in unusual feature binding. Finally, developmental synesthesia that occurs in individuals with autism may be a result of alterations in the serotonergic system, leading to a blockage of regular gating mechanisms. I conclude on these grounds that one commonality among at least some cases of acquired, developmental and drug-induced synesthesia may be the presence of excessive levels of serotonin, which increases the excitability and connectedness of sensory brain regions.
Research Summary of 'Serotonergic hyperactivity as a potential factor in developmental, acquired and drug-induced synesthesia'
Introduction
Brogaard frames synesthesia as a diverse set of conditions in which stimuli in one sensory or cognitive domain (the inducer) automatically elicit an additional, atypical percept or representation (the concurrent). She outlines three broad classes: developmental (lifelong, often familial and systematic), acquired (emerging after brain injury, disease or sensory substitution) and drug-induced (transient experiences during intoxication with psychedelics). Prior work implicates atypical structural or functional connectivity and mechanisms such as direct cross‑projection or disinhibited feedback, but little is known about common causal factors across the three classes. The paper sets out to develop and extend a serotonergic hypothesis: that excessive extracellular serotonin (5‑HT) or serotonergic agonism can trigger persistent or transient synesthesia across developmental, acquired and drug‑induced cases by increasing excitability and connectedness of sensory brain regions, principally via 5‑HT2A receptors on cortical neurons. Brogaard proposes to marshal evidence from studies of psychedelics, brain injury, autism and neuroimaging/genetics to evaluate whether a hyperserotonergic state could provide a unifying mechanistic factor for at least some instances of synesthesia.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Topics
- APA Citation
Brogaard, B. (2013). Serotonergic hyperactivity as a potential factor in developmental, acquired and drug-induced synesthesia. Frontiers in Human Neuroscience, 7. https://doi.org/10.3389/fnhum.2013.00657
References (6)
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)
Nichols, D. E. · Pharmacology and Therapeutics (2004)
Sinke, C., Halpern, J. H., Zedler, M. et al. · Consciousness and Cognition (2012)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Cited By (10)
Papers in Blossom that reference this study
Rieser, N. M., Gubser, L. P., Moujaes, F. et al. · Scientific Reports (2023)
Elman, I., Borsook, D., Pustilink, A. · Neuroscience and Biobehavioral Reviews (2022)
Luke, D., Lungu, L., Friday, R. et al. · Human Psychopharmacology (2021)
Aday, J. S., Bloesch, E. K., Wood, J. R. et al. · Reviews In The Neuroscience (2021)
Ramachandran, V., Chunharas, C., Marcus, Z. et al. · Neurocase (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Terhune, D. B., Luke, D. P., Kaelen, M. et al. · Neuropsychologia (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.